U.S. Markets closed
  • S&P 500

    3,901.36
    +0.57 (+0.01%)
     
  • Dow 30

    31,261.90
    +8.77 (+0.03%)
     
  • Nasdaq

    11,354.62
    -33.88 (-0.30%)
     
  • Russell 2000

    1,773.27
    -2.96 (-0.17%)
     
  • Crude Oil

    110.35
    +0.46 (+0.42%)
     
  • Gold

    1,845.10
    +3.90 (+0.21%)
     
  • Silver

    21.87
    -0.03 (-0.13%)
     
  • EUR/USD

    1.0562
    -0.0026 (-0.2429%)
     
  • 10-Yr Bond

    2.7870
    -0.0680 (-2.38%)
     
  • Vix

    29.43
    +0.08 (+0.27%)
     
  • GBP/USD

    1.2495
    +0.0020 (+0.1587%)
     
  • USD/JPY

    127.8500
    +0.0560 (+0.0438%)
     
  • BTC-USD

    29,552.46
    +216.86 (+0.74%)
     
  • CMC Crypto 200

    650.34
    -23.03 (-3.42%)
     
  • FTSE 100

    7,389.98
    +87.24 (+1.19%)
     
  • Nikkei 225

    26,739.03
    +336.19 (+1.27%)
     

Why Heron Therapeutics Shares Rose Nearly 15% This Week

·2 min read
Why Heron Therapeutics Shares Rose Nearly 15% This Week
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

The company announced on Thursday that its drug Zynrelef (bupivacaine and meloxicam) has been given Food and Drug Administration supplemental New Drug Application approval for more uses. The drug, the first FDA-approved dual-acting anesthetic, had already been approved in May for post-surgical pain relief after the removal of bunions, open inguinal hernia operations, or total knee replacement in adults. It has shown to be more effective than just bupivacaine alone, the current standard of care for post-surgical pain, and it gives surgeons a non-opioid solution for post-surgical pain, reducing the possibility of addiction.